Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Targeting Therapeutic T Cells to Tumour Niches.

Ben Carpenter, MD, Sara Ghorashian, MD, Emma Nicholson, MD, James Edward Griffin, MD, Maryam Ahmadi, PhD, Angelika Holler, Barry Flutter, PhD, Noha Edwards, Hans Stauss, MD, PhD, Emma Morris, MD, PhD, Ronjon Chakraverty, MD, PhD

Blood (2012) 120 (21): 3009.

https://doi.org/10.1182/blood.V120.21.3009.3009

Published: 2012

Journal Articles

Endogenous T Cell Receptors Drive Non-Specific Suppression by Foxp3 MHC Class I-Restricted T Cell Receptor-Transduced Polyclonal CD4+ T Cells in Models of Graft-Versus-Host Disease.

Benjamin J Uttenthal, MD, Emma Nicholson, MD, Ben Carpenter, MD, Sara Ghorashian, MD, Graham P Wright, PhD, Barry R Flutter, PhD, Shao-An Xue, PhD, Ronjon Chakraverty, MD, PhD, Emma Morris, MD, PhD

Blood (2012) 120 (21): 3152.

https://doi.org/10.1182/blood.V120.21.3152.3152

Published: 2012

Journal Articles

Enhancing the Efficacy of T Cell Receptor (TCR) Gene Therapy by Co-Transfer of TCR and Additional CD3 Molecules Into CD4+ T Cells

Emma K Nicholson, MD, Maryam Ahmadi, PhD, Angelika Holler, Rebecca Pike, PhD, Ben Carpenter, MD, Sharyn Thomas, PhD, Sara Ghorashian, MD, Shao-An Xue, PhD, Hans Stauss, MD, PhD, Emma Morris, MD, PhD

Blood (2012) 120 (21): 2044.

https://doi.org/10.1182/blood.V120.21.2044.2044

Published: 2012

Journal Articles

CD4 Cells Engineered to Express an MHC Class I Restricted TCR Can Rescue CD8 Cells Tolerized to Tumour-Associated Antigens

Sara Ghorashian, MD, Ben Carpenter, MD, Angelika Holler, Emma Nicholson, MD, Maryam Ahmadi, PhD, Mathias Zech, MD, Clare Bennett, PhD, Shao-An Xue, PhD, Emma Morris, MD, PhD, Hans Stauss, MD, PhD, Ronjon Chakraverty, MD, PhD

Blood (2012) 120 (21): 952.

https://doi.org/10.1182/blood.V120.21.952.952

Published: 2012

Journal Articles

Autologous Stem Cell Transplantation Using BEAM Conditioning Is Highly Effective in Patients with Follicular Lymphoma Regardless of Prior Rituximab Exposure

Jaimal Kothari, MD, Antonia Ljubic, BSc, Karl S Peggs, MD, Kirsty Thomson, MD, Emma Morris, MD, Andres E. Virchis, MD, Jonathan Lambert, MD, Anthony H Goldstone, MD, David C Linch, MD FMedSci, Kirit M Ardeshna, MD

Blood (2011) 118 (21): 2025.

https://doi.org/10.1182/blood.V118.21.2025.2025

Published: 2011

Journal Articles

Response-Adjusted Transplantation in Primary Resistant and Relapsed Hodgkin Lymphoma

Kirsty Thomson, Irfan Kayani, Kirit M Ardeshna, MD, Emma Morris, MD, Rachael Hough, Anthony H Goldstone, MD, David C Linch, MD FMedSci, Karl S Peggs, MD

Blood (2011) 118 (21): 336.

https://doi.org/10.1182/blood.V118.21.336.336

Published: 2011

Journal Articles

Positive Pre-Transplantation [18-F] FDG-PET Is Not a Barrier to Successful Allograft Outcomes in Chemosensitive Hodgkin Lymphoma

Karl S Peggs, Irfan Kayani, Kirsty Thomson, Emma Morris, MD, Panagiotis Kottaridis, Kirit M Ardeshna, MD, Adele Fielding, Rachael Hough, Anthony H Goldstone, MD, Ronjon Chakraverty, David C Linch, MD FMedSci, Stephen Mackinnon

Blood (2011) 118 (21): 2016.

https://doi.org/10.1182/blood.V118.21.2016.2016

Published: 2011

Journal Articles

A Simple Prognostic Score to Predict Short and Long-Term Survival Following ICU Admission in Critically Ill Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients: Improved Survival Following Reduced Intensity Conditioning

William Townsend, Ailsa Holroyd, Rachel M Pearce, Stephen Mackinnon, MD, Anthony H. Goldstone, FRCP, FRCPath, David C Linch, MD FMedSci, Karl S Peggs, MD, Kirsty Thomson, MD, Mervyn Singer, Prakesh Naik, David Howell, Emma Morris, MD

Blood (2011) 118 (21): 146.

https://doi.org/10.1182/blood.V118.21.146.146

Published: 2011

Journal Articles

Donor Lymphocyte Infusions Induce High Response Rates and Durable Salvage in Relapsed Hodgkin Lymphoma Post T Cell Depleted Allogeneic Transplantation.

Karl S Peggs, MD, Kirsty Thomson, MD, Emma Morris, MD, Noha Chowdhry, Stephanie Verfuerth, PhD, Panos Kottaridis, Anthony H. Goldstone, FRCP, FRCPath, Kirit Ardeshna, MD, David Linch, Ronjon Chakraverty, MD, PhD, Stephen Mackinnon, MD

Blood (2009) 114 (22): 200.

https://doi.org/10.1182/blood.V114.22.200.200

Published: 2009

Journal Articles

Phase I Study of Transfer of CD8 Depleted Donor Leukocytes after Allogeneic Stem Cell Transplantation.

Guillermo Orti, MD, Karl Peggs, MD, Kirsty Thomson, MD, Emma Morris, MD, Mark Lowdell, PhD, Stephen Mackinnon, MD, Ronjon Chakraverty, MD

Blood (2008) 112 (11): 2203.

https://doi.org/10.1182/blood.V112.11.2203.2203

Published: 2008

Journal Articles

Long-Term Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Aggressive Non-Hodgkins Lymphoma.

Kirsty Thomson, MD, Emma Morris, MD, Adrian Bloor, MD, Gordon Cook, MD, Donald Milligan, MD, Anne Parker, MD, Charles Craddock, MD, Lynny Yung, MD, Ronjon Chakraverty, MD, Karl Peggs, MD, Stephen Mackinnon, MD

Blood (2007) 110 (11): 1661.

https://doi.org/10.1182/blood.V110.11.1661.1661

Published: 2007

Journal Articles

Extended Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Follicular Lymphoma.

Kirsty Thomson, MD, Emma Morris, MD, Donald Milligan, MD, Ann Hunter, MD, Gordon Cook, MD, Adrian Bloor, MD, Charles Craddock, MD, Lynny Yung, MD, Anne Parker, MD, Ronjon Chakraverty, MD, Karl Peggs, MD, Stephen Mackinnon, MD

Blood (2007) 110 (11): 1666.

https://doi.org/10.1182/blood.V110.11.1666.1666

Published: 2007

Journal Articles

Multi-Center Phase II Study of CAMPATH-1H Dose De-Escalation Prior to Nonmyeloablative HLA-Identical Sibling Transplantation.

Ronjon Chakraverty, MD, Nilusha Manji, BSc, Richard Clark, MD, Charles Crawley, MD, Peter Johnson, MD, Effie Liakopoulou, MD, Judith Marsh, MD, Donald Milligan, MD, Emma Morris, MD, Karl Peggs, MD, Kirsty Thomson, MD, John Snowden, MD, Graham Jackson, MD, Stephen Mackinnon, MD

Blood (2007) 110 (11): 1055.

https://doi.org/10.1182/blood.V110.11.1055.1055

Published: 2007

Journal Articles

T Cell Receptor Gene Transfer to Produce MHC Class I-Restricted CD4 Helper T Cells: Implications for Immunotherapy of Leukaemia.

Emma Morris, MD, PhD, Aristotle Tsallios, MSc, Gavin Bendle, MSc, Shao-an Xue, PhD, Hans Stauss, MD, PhD

Blood (2004) 104 (11): 5262.

https://doi.org/10.1182/blood.V104.11.5262.5262

Published: 2004

NARROW

Targeting Therapeutic T Cells to Tumour Niches.

Endogenous T Cell Receptors Drive Non-Specific Suppression by Foxp3 MHC Class I-Restricted T Cell Receptor-Transduced Polyclonal CD4+ T Cells in Models of Graft-Versus-Host Disease.

Enhancing the Efficacy of T Cell Receptor (TCR) Gene Therapy by Co-Transfer of TCR and Additional CD3 Molecules Into CD4+ T Cells

CD4 Cells Engineered to Express an MHC Class I Restricted TCR Can Rescue CD8 Cells Tolerized to Tumour-Associated Antigens

Autologous Stem Cell Transplantation Using BEAM Conditioning Is Highly Effective in Patients with Follicular Lymphoma Regardless of Prior Rituximab Exposure

Response-Adjusted Transplantation in Primary Resistant and Relapsed Hodgkin Lymphoma

Positive Pre-Transplantation [18-F] FDG-PET Is Not a Barrier to Successful Allograft Outcomes in Chemosensitive Hodgkin Lymphoma

A Simple Prognostic Score to Predict Short and Long-Term Survival Following ICU Admission in Critically Ill Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients: Improved Survival Following Reduced Intensity Conditioning

Donor Lymphocyte Infusions Induce High Response Rates and Durable Salvage in Relapsed Hodgkin Lymphoma Post T Cell Depleted Allogeneic Transplantation.

Phase I Study of Transfer of CD8 Depleted Donor Leukocytes after Allogeneic Stem Cell Transplantation.

Long-Term Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Aggressive Non-Hodgkins Lymphoma.

Extended Follow-Up of Reduced Intensity Transplantation with an Alemtuzumab-Containing Regimen for Follicular Lymphoma.

Multi-Center Phase II Study of CAMPATH-1H Dose De-Escalation Prior to Nonmyeloablative HLA-Identical Sibling Transplantation.

T Cell Receptor Gene Transfer to Produce MHC Class I-Restricted CD4 Helper T Cells: Implications for Immunotherapy of Leukaemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only